Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GADD45B drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GADD45B Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for PPI binding assays. |
View GADD45B Products |
| Gene Delivery | GADD45B Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression validation. |
View GADD45B Products |
| Benchmark Ab | Anti-GADD45B Recombinant Antibody Sequence-verified positive control for Western Blot and IP. |
View GADD45B Products |
| Validator | GADD45B siRNA Set For knockdown verification in target validation assays. |
View GADD45B Products |
| Related Target A | MAP2K7 (MKK7) Direct binding partner of GADD45B; disrupting this PPI is a major therapeutic strategy. |
View MAP2K7 Products |
| Related Target B | MAPK8 (JNK1) Downstream kinase in the GADD45B/MKK7 cell survival pathway. |
View MAPK8 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Disruptor Screening (PPI Inhibition) | High-purity GADD45B and MKK7 partner proteins with verified theoretical MW and native-like folding. |
| Intracellular Delivery & Target Engagement | Lentiviral vectors optimized for high-efficiency transduction in hard-to-transfect myeloma cell lines. |
| Lack of Controls | Sequence-verified clinical-grade benchmark antibodies included. |
| False Positives in Small Molecule Screens | Validated siRNA sets included for target-specific knockdown control. |
Live GADD45B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GADD45B therapeutics is intensifying, with major players shifting focus from traditional systemic chemotherapy to targeted PPI (Protein-Protein Interaction) inhibitors. GADD45B is a pivotal anti-apoptotic factor regulated by NF-kB, specifically overexpressed in multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL). As first-generation peptide inhibitors reach early clinical evaluation, the next wave of R&D is targeting small-molecule PPI disruptors and PROTACs to achieve oral bioavailability and enhanced cellular penetration.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Peptide Inhibitors (e.g., DTP3) | Denception, Keapstone Therapeutics | Multiple Myeloma, DLBCL | Competitive Binding Assay (Need high-purity GADD45B/MKK7 recombinant proteins) |
| Small Molecule PPI | Academic Spin-offs, Biotech Startups | Solid Tumors, Inflammatory Diseases | Selectivity Screening (Need structural integrity and native-like folded proteins) |
| Gene Therapy / siRNA | Preclinical consortia | Rheumatoid Arthritis, Fibrosis | Knockdown Verification (Need high-titer Lentivirus and validated siRNA) |